Solesence Inc (OTC: SLSN) is a beauty, health, and wellness company that develops, manufactures, and markets scientifically driven skin health products including sun care formulations and active pharmaceutical ingredients. Revenue is generated through product sales of finished consumer goods and ingredient supply to beauty and wellness brand partners on a transactional basis. The company was incorporated in Illinois on November 25, 1989, operated for decades as Nanophase Technologies Corporation, and rebranded as Solesence, Inc. following a legal name change filed with Delaware on March 10, 2025. Core proprietary technologies include Kleair and Bloom platforms, applied across SPF-rated face oils, lip oils, and multi-use skin care formulations. The company operates as a contract developer and manufacturer for brand partners while also building its own consumer products subsidiary, Solesence LLC. Research and development expense totaled $4.1 million in FY2025 and $3.8 million in FY2024. Inventories stood at approximately $18.5 million net of a $2.7 million excess and obsolete reserve as of December 31, 2025.
Finished sun care and skin health formulations including Multi-Cultural Magic SPF 50+, Natural Glow Face Oil SPF 40+, and Lip Oil SPF 40+. Proprietary ingredient technologies Kleair and Bloom. Active pharmaceutical ingredients for skin health applications. Contract development and manufacturing services for beauty and wellness brands.
Transactional product sales of finished consumer goods and active pharmaceutical ingredient supply to beauty, health, and wellness brand partners. Additional revenue from legacy advanced materials applications.
Beauty, health, and wellness brands on a global basis. End markets include sun care, skin health, and consumer personal care. Customer concentration risk is noted in filings, with reference to risks from individual customer order cancellations.
Primary operations in the United States. Raw materials sourced from suppliers in China and Korea. Brand partnerships described as global in scope per the FY2025 10-K.
Loading...